相似文献
1
The generation and maintenance of serum alloantibody.
Curr Opin Immunol. 2010 Oct;22(5):669-81. doi: 10.1016/j.coi.2010.08.018.
2
Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival.
Hum Immunol. 2011 Jan;72(1):5-10. doi: 10.1016/j.humimm.2010.10.013. Epub 2010 Nov 10.
3
Donor-specific anti-HLA antibodies with antibody-mediated rejection and long-term outcomes following heart transplantation.
J Heart Lung Transplant. 2017 May;36(5):540-545. doi: 10.1016/j.healun.2016.10.016. Epub 2016 Nov 17.
4
Major histocompatibility complex class I-related chain A allele mismatching, antibodies, and rejection in renal transplantation.
Hum Immunol. 2011 Oct;72(10):827-34. doi: 10.1016/j.humimm.2011.05.004. Epub 2011 May 24.
5
IgM and IgG alloantibody responses to MHC class I and II following rat renal allograft rejection. Effects of transplantectomy and posttransplantation blood transfusion.
Transplantation. 1992 Jan;53(1):167-74. doi: 10.1097/00007890-199201000-00034.
6
Clinical significance of MHC-reactive alloantibodies that develop after kidney or kidney-pancreas transplantation.
Am J Transplant. 2002 Feb;2(2):134-41. doi: 10.1034/j.1600-6143.2002.020204.x.
7
Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
J Heart Lung Transplant. 2016 Jan;35(1):87-91. doi: 10.1016/j.healun.2015.08.008. Epub 2015 Sep 3.
8
Acute Antibody-Mediated Rejection in Presence of MICA-DSA and Successful Renal Re-Transplant with Negative-MICA Virtual Crossmatch.
PLoS One. 2015 May 29;10(5):e0127861. doi: 10.1371/journal.pone.0127861. eCollection 2015.
9
Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Clin Biochem. 2013 Oct;46(15):1389-93. doi: 10.1016/j.clinbiochem.2013.05.053. Epub 2013 May 29.
10
Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Transpl Immunol. 2013 Dec;29(1-4):28-33. doi: 10.1016/j.trim.2013.07.002. Epub 2013 Jul 29.
引用本文的文献
1
De Novo Donor-Specific Antibodies after Heart Transplantation: A Comprehensive Guide for Clinicians.
J Clin Med. 2023 Dec 2;12(23):7474. doi: 10.3390/jcm12237474.
2
Romidepsin (FK228) improves the survival of allogeneic skin grafts through downregulating the production of donor-specific antibody via suppressing the IRE1α-XBP1 pathway.
J Zhejiang Univ Sci B. 2022 May 15;23(5):392-406. doi: 10.1631/jzus.B2100780.
3
Detecting donor-specific antibodies: the importance of sorting the wheat from the chaff.
Hepatobiliary Surg Nutr. 2019 Feb;8(1):37-52. doi: 10.21037/hbsn.2019.01.01.
4
T Follicular Regulatory Cells and Antibody Responses in Transplantation.
Transplantation. 2018 Oct;102(10):1614-1623. doi: 10.1097/TP.0000000000002224.
5
MICA diversity and linkage disequilibrium with HLA-B alleles in renal-transplant candidates in southern Brazil.
PLoS One. 2017 Apr 18;12(4):e0176072. doi: 10.1371/journal.pone.0176072. eCollection 2017.
6
Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.
Sci Rep. 2017 Jan 24;7:41125. doi: 10.1038/srep41125.
7
B cells in transplantation.
J Heart Lung Transplant. 2016 Jun;35(6):704-10. doi: 10.1016/j.healun.2016.01.1232. Epub 2016 Feb 12.
8
Influence of immune responses in gene/stem cell therapies for muscular dystrophies.
Biomed Res Int. 2014;2014:818107. doi: 10.1155/2014/818107. Epub 2014 May 19.
9
Human α1-antitrypsin modifies B-lymphocyte responses during allograft transplantation.
Immunology. 2013 Nov;140(3):362-73. doi: 10.1111/imm.12149.
10
A preliminary study for constructing a bioartificial liver device with induced pluripotent stem cell-derived hepatocytes.
Biomed Eng Online. 2012 Dec 7;11:93. doi: 10.1186/1475-925X-11-93.
本文引用的文献
1
Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow.
Blood. 2010 Sep 16;116(11):1867-75. doi: 10.1182/blood-2009-12-259457. Epub 2010 Jun 10.
2
Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis.
J Immunol. 2010 Jul 1;185(1):717-28. doi: 10.4049/jimmunol.0903589. Epub 2010 Jun 4.
3
Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.
Transplantation. 2010 Jul 15;90(1):68-74. doi: 10.1097/TP.0b013e3181e065de.
4
Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses.
Transplantation. 2010 May 27;89(10):1239-46. doi: 10.1097/TP.0b013e3181d72091.
5
FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications.
Nat Rev Immunol. 2010 May;10(5):328-43. doi: 10.1038/nri2762.
6
B cells and plasma cells in coronaries of chronically rejected cardiac transplants.
Transplantation. 2010 May 15;89(9):1141-8. doi: 10.1097/TP.0b013e3181d3f271.
7
Efficacy of induction therapy with ATG and intravenous immunoglobulins in patients with low-level donor-specific HLA-antibodies.
Am J Transplant. 2010 May;10(5):1254-62. doi: 10.1111/j.1600-6143.2010.03093.x. Epub 2010 Mar 26.
8
Renal transplantation across HLA and ABO antibody barriers: integrating paired donation into desensitization protocols.
Am J Transplant. 2010 Mar;10(3):449-57. doi: 10.1111/j.1600-6143.2009.03001.x. Epub 2010 Feb 1.
9
Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation.
Am J Transplant. 2010 Mar;10(3):582-9. doi: 10.1111/j.1600-6143.2009.02985.x. Epub 2010 Jan 29.
10
Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
Transplantation. 2010 May 15;89(9):1095-102. doi: 10.1097/TP.0b013e3181d21e7f.
Zotero 插件